Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-

  • End date
    Oct 31, 2023
  • participants needed
  • sponsor
    Beijing Tiantan Hospital
Updated on 5 August 2021


A Phase , Multicenter, Prospective, Randomized, Open Label, Blinded-endpoint (PROBE) Controlled Trial of Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) for Injection Versus Alteplase for Acute Ischemic Stroke Within 4.5 Hours


To test the hypothesis that rhTNK-tPA is non-inferior to alteplase in thrombolysis treatment when administered within 4.5 hours of ischemic stroke onset.

Condition Acute Ischemic Stroke
Treatment rt-PA, rhTNK-tPA
Clinical Study IdentifierNCT04797013
SponsorBeijing Tiantan Hospital
Last Modified on5 August 2021


Yes No Not Sure

Inclusion Criteria

Age 18 years old, no gender limitation
The time from onset to treatment was < 4.5h;The time at which symptoms begin is defined as "the time at which they finally appear normal
The clinical diagnosis was ischemic stroke (the diagnosis followed the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018)
MRS before onset was 0-1 points
Baseline NIHSS 5-25(both included)
Informed consent from the patient or surrogate

Exclusion Criteria

Intended to proceed endovascular treatment
NIHSS consciousness score >2
Allergy to tenecteplase or alteplase
Past history of intracranial hemorrhage
A history of severe head trauma or stroke within 3 months
A history of intracranial or spinal surgery within 3 months
A history of gastrointestinal or urinary bleeding within 3 weeks
weeks of major surgery
Arterial puncture was performed at the hemostasis site that was not easily compressed within 1 week
Intracranial tumors (except neuroectodermal tumors, such as meningiomas), large intracranial aneurysms
Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.)
Active visceral bleeding
Aortic arch dissection was found
After active antihypertensive treatment, hypertension is still not under control: systolic blood pressure 180 mm Hg, or diastolic blood pressure 100 mm Hg
Propensity for acute bleeding, including platelet counts of less than 100109/ L or otherwise
Blood glucose <2.8 mmol/L or >22.22 mmol/L
Oral warfarin anticoagulant with INR>1.7 or PT>15 s
Heparin treatment was received within 24 h
Thrombin inhibitors or factor Xa inhibitors were used within 48 h
Head CT or MRI showed a large infarction (infarcted area > 1/3 of the middle cerebral artery)
Subjects who are unable or unwilling to cooperate due to hemiplegia (Todd's palsy) after epileptic seizure or other neurological/psychiatric disorders
Pregnant women, lactating women, or subjects who do not agree to use effective contraception during the trial
Participation in other clinical trials within 3 months prior to screening
Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note